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Reply to: ‘‘Network-based discovery of gene signature
for vascular invasion prediction in HCC’’
A more relevant question is when can our signature-alone or
in combination with tumor size- be translated into clinical prac-
tice. Strict rules have been proposed recently by Simon and col-
leagues [7]. Following this proposal, the EASL-EORTC guidelines
on management of HCC have outlined a list of requirements in
order to adopt molecular signatures in the clinical practice [8],
which are as follows:
1. First, the signature should be generated in the setting of ran-
domized studies or in case of cohort studies, it should follow
the training/validation approach.
2. The signature should retain independent prognostic value
when tested along known clinico-pathological variables.
3. The results should be conﬁrmed by independent investigators
in a separate set of samples.
Thus, according to these rules, in order to implement our sig-
nature in the decision-making process, for instance in the waiting
Letters to the EditorTo the Editor:
Liu and colleagues raise some issues regarding our recently pub-
lished study [1] to which we would like to make the following
comments. We acknowledge the limitations that a gene-expres-
sion-based biomarker could have, and that our signature is not
unique. Certainly, previous attempts to ﬁnd such a signature have
been published in the past [2]. We also know that, as in other
gene expression studies, potential bias could occur. In fact,
reported prognostic signatures are often not reproducible, in
most of the cases due to suboptimal study design, small sample
sizes, and also because many of them have been based on retro-
spectively collected tissue samples [3]. Even after taking into
account these sources of bias or inconsistencies, it so happens
that only a small minority of the reported signatures truly retain
prognostic signiﬁcance. In fact, our recent outcome analysis
including 22 gene signatures with prognostic signiﬁcance in
HCC (18 from the tumor, and four from the non-tumoral adjacent
tissue) showed that only two signatures retained independent
prognostic value [4].In our work, we select a training cohort based upon a homo-
geneous etiology to minimize the risk of molecular heterogene-
ity and to identify a clean and distinct signature. Patients with
HCV-related HCC were selected, since this is the most common
etiology in the Western countries. Then, we validate the signa-
ture in an independent multi-etiologic cohort of patients and
the accuracy remained stable when an etiology-dependent sub-
group analysis was performed [1]. The study was aimed at pro-
viding a gene-set to ease the preoperative diagnosis of vascular
invasion, but was not designed for deﬁning outcome prediction.
Nonetheless, we have data indicating that the presence of a vas-
cular invasion signature correlates with poor outcome, since the
signature was found to be associated with early recurrence
(p = 0.057), and was enriched in patients sharing signatures of
poor prognosis [4].
Even considering that the question posed is simple (to identify
a gene-signature capturing vascular invasion) the characteristics
of patients, sample collection, sampling issues, technical varia-
tion, validation of results, and bioinformatics approaches are cer-
tainly heterogeneous, and thus the results might vary. In most
instances, however, the different signatures seem to be able to
capture common oncogenic mechanisms, as reﬂected by their
capacity to adequately allocate patients into a poor or good prog-
nosis group [5]. By applying a different methodological approach
(weighted gene co-expression network analysis) to our data, Liu
et al. provide a 9-gene signature with similar accuracy and no
overlap with our 35-gene signature. The method applied is based
on systems biology to ﬁnd clusters of highly correlated genes
across microarray samples, identify hubs of each module and cor-
relate them with clinical traits [6]. This analysis is based on the
hypothesis that information on signaling pathways is crucial to
understand how genes are connected to each other and how they
inﬂuence cellular functions in both normal and cancer conditions.
This result further underlines the need for integrating the vast
amount of available data and the development of powerful bioin-
formatics resources (annotation, methodologies, technical plat-
forms, etc.).
list of liver transplantation, it should be validated by independent
investigators in a novel set of samples. Ideally, the signature has
to be reproduced in a device, which should give similar results.
Only then, data is ready for acceptance in guidelines. It is a long
path, but the only one for translation of genomic results into our
practice.
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Deregulation of microRNAs expression occurs in stages of multistep
hepatocarcinogenesis: Why is it different?
To the Editor:
HBV is a major cause of acute and chronic liver infection, and can
lead to hepatitis, cirrhosis, and hepatocellular carcinoma (HCC)
[1], which is the ﬁfth most common cancer and the third leading
cause of cancer death worldwide. More than 80% of HCC patients
are in developing countries, especially in Southeast Asia and sub-
Saharan Africa. However, the incidence of HCC has been rising in
Western countries in recent years [2]. The current standard of
care and therapy for patients with advanced HCC are not satisfac-
tory. Surgical resection or liver transplantation remains the most
effective treatment options for HCC, but few patients are fortu-
nate to get the treatment, for all kinds of reasons. Therefore,
the analysis of the molecular mechanisms of oncogenesis is badly
needed to uncover novel targets for speciﬁc systemic therapy and
to discover novel biomarkers for early diagnosis of HCC.
MicroRNAs (miRNAs), which are endogenous, small non-cod-
ing RNAs consisting of 20–25 nucleotides, have been shown to
play important roles in various cellular and physiological pro-
cesses, including cellular development, apoptosis, proliferation,
and differentiation [3,4]. Typically, they modulate gene expres-
sion by regulating the mRNA at a posttranscriptional stage,
base-pairing with sequences in the 30-untranslated region [3,5].
There are currently 940 identiﬁable humanmiRNAs (The miRBase
Sequence Database-Release ver. 15.0), which can recognize hun-
dreds of target genes with incomplete complementarity and over
one third of human genes appear to be conserved miRNA targets
[6]. Recent evidence clearly shows that deregulation of miRNAs
may contribute to aberrant activation of oncogenes and inactiva-
tion of tumor suppressor genes in human carcinogenesis. Several
miRNAs have been linked to the initiation and progression of
human cancers, including HBV-associated HCC [7–10]. Thus, great
efforts have been put on miRNA mimetics and anti-sense miRNA
as potential therapeutics for hepatocellular carcinoma, due to
their stability and predominant uptake by the liver.
In the study by Gao et al. [7], a panel of seven miRNAs (miR-
10b, miR-21, miR-122, miR-145, miR-199b, miR-221, and miR-
224) was selected to examine miRNA deregulation during early
stages of hepatocarcinogenesis. Among these miRNAs, only
miR-145, miR-199b, and miR-224 were found to be signiﬁcantly
deregulated during the multistep hepatocarcinogenesis. While
other miRNAs’ expression changes seldom reached statistically
signiﬁcant levels among non-tumorous livers, dysplastic nodules
and small HCC, after Bonferroni correction for multiple compari-
son tests [7]. This conclusion was quite different from other study
results. Pineau et al. concluded that among the miRNAs present in
the progression signature, miR-221 was capable of stimulating
tumor growth in vivo possibly through p27 and/or DDIT4 down-
regulation [8]. The ﬁndings of Kutay et al. suggested that miR-122
downregulation was associated with hepatocarcinogenesis and
could be a potential biomarker for liver cancer [9]. Connolly
et al. initial analysis of cirrhotic livers suggested that upregula-
tion of miR-17-92 and miR-21 occurred in pre-cancerous stages
of liver disease [10]. Then, which conclusion is more convincing?
And what makes them into controversies?
Despite the difference in the methods used by the research-
ers, the development of hepatocellular carcinoma in individuals
with chronic hepatitis B is a multistage, multifactorial process
including the interaction between host and environmental
factors [11]. Risk factors for chronic HBV-related hepatocellular
carcinoma include HBV DNA level, sex, age, cigarette smoking,
alcohol consumption, chemical carcinogens, hormonal factors,
and genetic susceptibility [12]. In a previous study, Zhang
et al. [13] demonstrated that perturbations of miRNA expression
during HBV infection were signiﬁcantly correlated with those in
HCC, and that aberrant expression of miR-199a, miR-199a⁄,
miR-200a, and miR-200b was associated with liver ﬁbrosis
progression. In addition, the work by Liu et al. [14] suggested
that microRNA-18a prevented estrogen receptor expression,
promoting proliferation of hepatocellular carcinoma cells, which
could be a mechanism explaining the sex disparity observed in
HCC. However, the relationship between miRNA expression and
other risk factors for chronic HBV-related HCC remains elusive.
In the past studies, scientists paid most of their attention on
the miRNA expression changes during the process of HCC, with-
out taking other risk factors for chronic HBV-related HCC into
consideration. Even though more and more miRNAs are being
reported to be frequently deregulated in human cancers and
may play a role in liver carcinogenesis, it is difﬁcult to judge
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